HX008
Success Metrics
Phase Distribution
Phase Distribution
3
Early Stage
5
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
0.0%
0 of 0 finished
0.0%
0 ended early
0
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma
A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors
A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma
A Study of HX008 for the Treatment of Patients With Malignant Melanoma
HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer
Clinical Trials (9)
MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma
A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors
A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma
A Study of HX008 for the Treatment of Patients With Malignant Melanoma
HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer
Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9